Literature DB >> 8750531

Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.

H Inaji1, H Koyama, K Motomura, S Noguchi.   

Abstract

We examined the expression of ErbB-2 and pS2 proteins in 59 ductal carcinoma in situ (DCIS) of the breast, either pure DCIS or DCIS associated with invasive carcinoma, using immunohistochemical staining of paraffin-embedded sections. Positive staining for ErbB-2 and pS2 proteins was noted in 32% (19/59) and 46% (27/59) of DCIS, respectively. An inverse relationship between ErbB-2 and pS2 status in DCIS was observed (p < 0.01). From the viewpoint of histological subtype, the prevalence of ErbB-2 protein expression was significantly higher in the comedo subtype than the cribriform-micropapillary subtype. The prevalence of immunoreactivity for ErbB-2 in solid subtype was intermediate between those of the other two groups. In contrast, the prevalence of pS2 expression was significantly lower in the comedo subtype than in the cribriform-micropapillary subtype. Again, the prevalence of pS2 protein expression in the solid subtype was intermediate between those of the other two subtypes. Our results suggest that DCIS is biologically heterogeneous with regard to such marker substances. This has possible implications for management of these lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8750531     DOI: 10.1007/bf01806635

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy.

Authors:  S J Schnitt; J L Connolly; U Khettry; G Mazoujian; M Brenner; B Silver; A Recht; G Beadle; J R Harris
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

4.  Recurrence after lumpectomy for comedo-type intraductal carcinoma of the breast.

Authors:  R M Baird; A Worth; G Hislop
Journal:  Am J Surg       Date:  1990-05       Impact factor: 2.565

5.  Flow cytometric and histological analysis of ductal carcinoma in situ of the breast.

Authors:  A P Locker; C Horrocks; A S Gilmour; I O Ellis; C S Dowle; C W Elston; R W Blamey
Journal:  Br J Surg       Date:  1990-05       Impact factor: 6.939

6.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.

Authors:  B Fisher; J Costantino; C Redmond; E Fisher; R Margolese; N Dimitrov; N Wolmark; D L Wickerham; M Deutsch; L Ore
Journal:  N Engl J Med       Date:  1993-06-03       Impact factor: 91.245

7.  Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment.

Authors:  L J Solin; I T Yeh; J Kurtz; A Fourquet; A Recht; R Kuske; B McCormick; M A Cross; D J Schultz; R Amalric
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

8.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Authors:  L H Schwartz; F C Koerner; S M Edgerton; J M Sawicka; M C Rio; J P Bellocq; P Chambon; A D Thor
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

9.  Estrogen receptor immunohistochemistry in carcinoma in situ of the breast.

Authors:  M E Bur; M J Zimarowski; S J Schnitt; S Baker; R Lew
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

10.  Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.

Authors:  Y A Luqmani; T Campbell; S Soomro; S Shousha; M C Rio; R C Coombes
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more
  1 in total

1.  Recent Progress in Breast Conserving Therapy: From Experiences in Japan.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.